Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy
Oral Diseases · 2024
DOI: 10.1111/odi.14854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Hsueh-Ju Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Head and Neck Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Objective
Immune checkpoint inhibitors (ICI) are recommended as the first‐line therapy for platinum‐refractory head and neck squamous cell carcinoma (HNSCC), a disease with a poor prognosis. However, biomarkers in this situation are rare. The objective was to identify radiomic features‐associated biomarkers to guide the prognosis and treatment opinions in the era of ICI.
Methods
A total of 31 platinum‐refractory HNSCC patients were retrospectively enrolled. Of these, 65.5% (20/31) received ICI‐based therapy and 35.5% (11/31) did not. Radiomic features of the primary site at the onset of recurrent metastatic (R/M) status were extracted. Prognostic and predictive radiomic biomarkers were analysed.
Results
The median overall survival from R/M status (R/M OS) was 9.6 months. Grey‐level co‐occurrence matrix‐associated texture features were the most important in identifying the patients with or without 9‐month R/M death. A radiomic risk‐stratification model was established and equally separated the patients into high‐, intermittent‐ and lower‐risk groups (1‐year R/M death rate, 100.0% vs. 70.8% vs. 27.1%, p = 0.001). Short‐run high grey‐level emphasis (SRHGE) was more suitable than programmed death ligand 1 (PD‐L1) expression in selecting whether patients received ICI‐based therapy.
Conclusions
Radiomic features were effective prognostic and predictive biomarkers. Future studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
- College of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Department of Stomatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
- College of Oral Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Pathology, Chung Shan Medical University and Hospital, Taichung, Taiwan.
ORCID-Profile: Hsueh-Ju Lu
Zitieren
APA
Lu, H. J., Shen, C. Y., Chiu, Y. W., Lin, W. L., Peng, C. Y., Tseng, H. C., Hsin, C. H., Chuang, C. Y., Chen, C. C., Wu, M. F., Huang, W. S., & Shen, W. C. (2024). Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy. Oral Diseases. https://doi.org/10.1111/odi.14854
Vancouver
Lu HJ, Shen CY, Chiu YW, Lin WL, Peng CY, Tseng HC, et al. Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy. Oral Diseases. 2024. doi:10.1111/odi.14854
BibTeX
@article{Lu2024,
author = {Lu, Hsueh-Ju and Shen, Chao-Yu and Chiu, Yu-Wei and Lin, Wea-Lung and Peng, Chih-Yu and Tseng, Hsien-Chun and Hsin, Chung-Han and Chuang, Chun-Yi and Chen, Chun-Chia and Wu, Ming-Fang and Huang, Wei-Shiou and Shen, Wei-Chih},
title = {Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14854}
}
EUVIMED